ABC | Volume 114, Nº3, Março 2020

Minieditorial Cardoso e D’Avila AODs Ininterruptos em Ablação de FA Arq Bras Cardiol. 2020; 114(3):443-445 Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 4. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J,Wilber DJ, et al., and Investigators V-A. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36(:1805-11. 5. Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, et al., and Investigators R-C. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Engl J Med . 2017;376(17):1627-36. 6. Cardoso R, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH,et al. Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials. Clin Cardiol . 2019;42(1):198-205. 7. Lakshmanadoss U, WongWS, Kutinsky I, KhalidMR, Williamson B , Haines DE. Figure-of-eight suture for venous hemostasis in fully anticoagulated patients after atrial fibrillation catheter ablation. Indian Pacing Electrophysiol J . 2017;17(5):134-9. 8. Nogami A, Harada T, Sekiguchi Y, Otani R, Yoshida Y, Yoshida K, et al. , and Investigators A-J. Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial. JAMA Netw Open . 2019;2(4):e191994. 445